leadf
logo-loader
viewCo-Diagnostics

Co-Diagnostics expects to roll out its coronavirus detection test in Europe shortly

The test uses the Utah company’s CoPrimer technology to identify the presence of ribonucleic acid (RNA) associated with a new strain of the deadly virus

Co-Diagnostics -
Co-Diagnostics will manufacture its coronavirus diagnostic test in a plant set up for the manufacturing of IVD medical devices in Utah

Co-Diagnostics Inc (NASDAQ:CODX) is on the receiving end of good news as its Logix Smart COVID-19 test, which detects the deadly coronavirus, is close to being rolled out across the European Union after being submitted for formal EU registration.

This novel test uses the Utah diagnostics company’s CoPrimer technology to identify the presence of a ribonucleic acid (RNA) associated with a new strain of the sometimes fatal virus, which first struck in the city of Wuhan in China late last year. The virus has since spread from China to infect more than 75,000 people and cause nearly 2,130 deaths, according to data cited by Johns Hopkins Center for Systems Science and Engineering.

READ: Co-Diagnostics receives new orders for its vector control tests, equipment from mosquito abatement districts

The coronavirus diagnostic test is expected to be available this month in European countries which accept the highly sought-after CE marking as valid regulatory approval.

“We are pleased to announce this milestone, which comes after weeks of hard work by our team at Co-Diagnostics to develop a high-performance diagnostic to help prevent the spread of the new strain of coronavirus,” says Dwight Egan, CEO of Co-Diagnostics.

“Our patented CoPrimer molecules have unique properties that lead to a significant reduction in false positive test results over other polymerase chain reaction (PCR), but will also allow for enhanced multiplexing, or identifying multiple targets at once, as we iterate the test to include other strains of coronavirus and mutations of COVID-19.”

The dossier with the relevant technical file, which was submitted to the Utah company’s European representative, includes a description of the test to support its compliance with the necessary standards to win a CE mark. This information will confirm the test meets the requirements of the European Union’s In-Vitro Diagnostic (IVD) Medical Device directive.

Co-Diagnostics will manufacture its coronavirus diagnostic test in a plant set up for the manufacturing of IVD medical devices in Utah.

Earlier this month, Co-Diagnostics’ coronavirus diagnostic test caught the eye of analysts at Maxim Group. Enthusiastic about its introduction in China, Maxim analysts tagged the company with a Buy rating and increased its price target to $5 from $2, citing the speed at which the company developed the detection test and its first sales in China.

Co-Diagnostics shares moved 6.3% higher to hit $3.20 in afternoon trade on Thursday.

Quick facts: Co-Diagnostics

Price: 11.04 USD

NASDAQ:CODX
Market: NASDAQ
Market Cap: $309.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020

2 min read